journal article·2026-04Open access

Ion-activated mucoadhesive in situ gel incorporating terbinafine-loaded NLCs promotes ocular penetration and retention for enhanced fungal keratitis therapy

Fudan Dong, Zhen Liang, Xiaping Yao, Zhen Zhang, Yuan Tao, Hui Chen, Ping Lu, Huiyun Xia, Junjie Zhang, Guojuan Pu, Tianyang Zhou

Abstract

Fungal keratitis (FK) is a sight-threatening infection with poor outcomes due to rapid tear clearance and insufficient corneal penetration. To overcome the limitations, we developed an ion-activated mucoadhesive in-situ gelling system (TH-NLC-ISG) integrating terbinafine-loaded nanostructured lipid carrier (TH-NLC) into a gellan gum/carboxymethyl chitosan matrix. The optimized formulation exhibited a particle size of 25.27 ± 0.75 nm. Upon contact with simulated tear fluid, the formulation underwent rapid sol-gel transition, achieving a 70-fold viscosity increase (34°C, shear rate 1 s -1 ), critical for prolonged ocular residence. Fluorescence imaging demonstrated ocular retention of fluorescein sodium-labeled TH-NLC-ISG exceeding 60 min, significantly longer than the non-gelling control. In vivo pharmacokinetic studies revealed markedly improved ocular bioavailability, with higher area under the concentration in ocular tissues-time curve of TH in the TH-NLC-ISG group compared to TH-NLC. Corneal penetration studies confirmed that TH-NLC-ISG exhibited longer corneal retention time and higher corneal drug retention compared to TH-NLC. The formulation demonstrated excellent ocular biocompatibility in vitro and in vivo . TH-NLC-ISG exhibited potent in vitro antifungal activity against Fusarium solani. and Aspergillus flavus. , with a lower MIC 50 value than TH suspension. In rabbits and mice FK models, TH-NLC-ISG group achieved complete corneal healing, reduced clinical scores and corneal perforation rates, displaying efficacy superior to conventional natamycin eye drops. By synergistically augmenting retention and corneal permeation, TH-NLC-ISG provides a transformative strategy for enhanced fungal keratitis therapy. • An innovative ion-activated in situ gelling system integrating nanostructured lipid carriers (NLCs) into a gellan gum/carboxymethyl chitosan (GG/CMCS) matrix was engineered. • The formulation utilizes an ion-triggered sol-gel transition (70-fold viscosity increase) and electrostatic mucoadhesion to overcome rapid tear clearance. • Synergy between NLCs (penetration) and smart hydrogel (retention) significantly enhanced ocular bioavailability and corneal drug retention. • The therapeutic platform demonstrated superior efficacy over commercial natamycin in resolving fungal keratitis in animal models.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Ocular Surface and Contact Lens · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (47)

Show source-provided references
1. Six-year analysis of the pathogenic spectrum, risk factors, and prognosis of non-traumatic fungal keratitis in Northern China10.1111/ceo.14314 ↗
2. Fungal keratitis: a review of clinical presentations, treatment strategies and outcomes10.1016/j.jtos.2021.12.001 ↗
3. The global incidence and diagnosis of fungal keratitis10.1016/S1473-3099(20)30448-5 ↗
4. Mycotic Keratitis-A global threat from the filamentous fungi10.3390/jof7040273 ↗
5. Trans-corneal drug delivery strategies in the treatment of ocular diseases10.1016/j.addr.2023.114868 ↗
6. Topical ocular drug delivery systems: innovations for an unmet need10.1016/j.exer.2022.109006 ↗
7. Ocular drug delivery: present innovations and future challenges10.1124/jpet.119.256933 ↗
8. Recent progress of solid lipid nanoparticles and nanostructured lipid carriers as ocular drug delivery platforms10.3390/ph16030474 ↗
9. In situ gelling systems for ocular drug delivery10.1016/j.jconrel.2024.05.031 ↗
10. Optimization of nanostructured lipid carriers: understanding the types, designs, and parameters in the process of formulations10.1007/s11051-020-04848-0 ↗
11. The effect of charges on the corneal penetration of solid lipid nanoparticles loaded Econazole after topical administration in rabbits10.1016/j.ejps.2023.106494 ↗
12. Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: development, in-vitro and in vivo study10.1080/10717544.2022.2048134 ↗
13. Dasatinib and erianin co-loaded ion-responsive in-situ hydrogel for effective treatment of corneal neovascularization10.1016/j.jconrel.2024.10.001 ↗
14. Formulation and evaluation of nano lipid carrier-based ocular gel system: optimization to antibacterial activity10.3390/gels8050255 ↗
15. Potential of vB_Pa_ZCPS1 phage embedded in situ gelling formulations as an ocular delivery system to attenuate Pseudomonas aeruginosa keratitis in a rabbit model10.1016/j.jconrel.2025.01.091 ↗
16. A stemness‐enhanced eye drop stimulates corneal regeneration via sustained release of versican and providing lubricated substrate10.1002/adfm.202411735 ↗
17. pH sensitive in-situ gel for ophthalmic delivery of ofloxacin and dexamethasone sodium phosphate: formulation, development, and evaluation10.1016/j.matpr.2023.07.161 ↗
18. Development and characterization of dual-loaded niosomal ion-sensitive in situ gel for ocular delivery10.3390/gels10120816 ↗
19. Gellan gum-based in-situ gel formulations for ocular drug delivery: a practical approach10.1016/j.ijbiomac.2024.138979 ↗
20. Gel properties and interactions of hydrogels constructed with low acyl gellan gum and puerarin10.1016/j.carbpol.2023.121594 ↗
21. Multifunctional pH-responsive hydrogel dressings based on carboxymethyl chitosan: synthesis, characterization fostering the wound healing10.1016/j.carbpol.2024.122348 ↗
22. A dual-functional chitosan derivative platform for fungal keratitis10.1016/j.carbpol.2021.118762 ↗
23. Novel topical formulations of Terbinafine-HCl for treatment of onychomycosis10.1016/j.ejps.2012.12.014 ↗
24. Natamycin ocular delivery: challenges and advancements in ocular therapeutics10.1007/s12325-023-02541-x ↗
25. In vitro activity of novel antifungals, natamycin, and terbinafine against Fusarium10.1128/aac.01913-24 ↗
26. Preparation, characterisation, and topical delivery of terbinafine10.3390/pharmaceutics11100548 ↗
27. In vitro and in vivo evaluation of Gelrite® gellan gum-based ocular delivery system for indomethacin
28. Sustained ophthalmic delivery of ofloxacin from an ion-activated in situ gelling system
29. Micelle carriers based on macrogol 15 hydroxystearate for ocular delivery of terbinafine hydrochloride: in vitro characterization and in vivo permeation10.1016/j.ejps.2017.08.020 ↗
30. Assessment to the antifungal effects in vitro and the ocular pharmacokinetics of solid-lipid nanoparticle in rabbits10.2147/IJN.S340068 ↗
31. Development of in situ-gelling and mucoadhesive acetaminophen liquid suppository10.1016/S0378-5173(97)00386-4 ↗
32. Biophilic positive carbon dot exerts antifungal activity and augments corneal permeation for fungal keratitis10.1021/acs.nanolett.4c01042 ↗
33. Novel nanomicelle butenafine formulation for ocular drug delivery against fungal keratitis: in vitro and in vivo study10.1016/j.ejps.2023.106629 ↗
34. Comparison of the different protocols of the Hen's Egg Test-Chorioallantoic Membrane (HET-CAM) by evaluating the eye irritation potential of surfactants
35. Celastrol-based nanomedicine promotes corneal allograft survival10.1186/s12951-021-01079-w ↗
36. Rabbit fungal keratitis model of Fusarium solani tested against three commercially available antifungal drugs10.1097/ICL.0000000000000689 ↗
37. Rabbit model of aspergillus keratitis induced by modified corneal surface lens method
38. Gallic acid ameliorates Aspergillus fumigatus keratitis through reducing fungal load and suppressing the inflammatory response10.1167/iovs.63.12.12 ↗
39. Experimental keratomycosis in a mouse model10.1167/iovs.02-0446 ↗
40. Solubility enhancement of terbinafine hydrochloride by hydrotropic technique
41. In vivo assembly drug delivery strategy based on ultra-small nanoparticles: toward high drug permeation and accumulation for CNV treatment10.1016/j.cej.2022.137968 ↗
42. Cubosomal lipid nanoassemblies with pH-sensitive shells created by biopolymer complexes: a synchrotron SAXS study10.1016/j.jcis.2021.08.187 ↗
43. Nanoemulsion-based pseudopolyrotaxane hydrogel for enhanced corneal bioavailability and treatment of corneal inflammation10.1016/j.jconrel.2024.12.075 ↗
44. Influence of HA on release process of anionic and cationic API incorporated into hydrophilic gel10.3390/ijms24065606 ↗
45. Drug-peptide supramolecular hydrogel boosting transcorneal permeability and pharmacological activity via ligand-receptor interaction
46. Terbinafine: mode of action and properties of the squalene epoxidase inhibition10.1111/j.1365-2133.1992.tb00001.x ↗
47. Detailed mechanism of squalene epoxidase inhibition by terbinafine10.1021/ci100403b ↗